Treatment options for patients with epithelioid hemangioendothelioma vary dependent on disease status, but more therapies are ...

Non-small cell lung cancer is the most common type of lung cancer. Learn about its causes, symptoms, and new treatments that may slow its progression and improve quality of life.

Novartis moves to block cancer drug generic in US ...

Novartis AG renewed its courtroom campaign to block copies of its cancer drug Mekinist, alleging that generics proposed by Teva Pharmaceutical Industries Ltd. infringe four patents for the lucrative ...

Novartis (NVS) reported $14.05 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 9.2%. EPS of $2.42 for the same period compares to $1.97 a year ago. The ...

Swiss pharma giant Novartis AGNVS reported better-than-expected results for the second quarter of 2025 and upped annual guidance for core operating income. Core earnings (excluding one-time charges) ...

Novartis is a “pure-play” innovative medicines company. We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple ...

The trend likely continued into the second quarter as well. Other growth drivers, such as Zolgensma, Lutathera, Jakavi and Tafinlar + Mekinist, have likely witnessed an increase in demand. However, ...